Literature DB >> 24433179

Autoreactive T cells in the immune pathogenesis of pemphigus vulgaris.

Kyle T Amber1, Patrick Staropoli, Michael I Shiman, George W Elgart, Michael Hertl.   

Abstract

Pemphigus vulgaris is a life-threatening autoimmune blistering disease caused by anti-desmoglein IgG autoantibodies that finally lead to acantholysis presenting clinically as progressive blistering. Whilst the production of pathogenic antibodies is key to the development of pemphigus vulgaris, many immunological steps are required prior to autoantibody induction. We review advances in the understanding of these immunologic processes with a focus on human leucocyte antigen polymorphisms and antigen recognition, epitope spreading, central and peripheral tolerance, T helper differentiation, induction of pro- and anti-inflammatory cytokines and T-cell regulation of B cells. Targeting autoaggressive T cells as regulators and stimulators of B-cell antibody production should allow for more specific therapeutic immune interventions, avoiding the global immunosuppression seen with many commonly used immunosuppressants in pemphigus vulgaris.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  B cell; HLA class II; T cell; autoantigen; desmoglein; pemphigus vulgaris; rituximab

Mesh:

Substances:

Year:  2013        PMID: 24433179     DOI: 10.1111/exd.12229

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  14 in total

Review 1.  [Pemphigus. Model disease for targeted therapy].

Authors:  R Eming
Journal:  Hautarzt       Date:  2015-08       Impact factor: 0.751

Review 2.  Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches.

Authors:  Robert Pollmann; Thomas Schmidt; Rüdiger Eming; Michael Hertl
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

Review 3.  Targeted Therapies for Autoimmune Bullous Diseases: Current Status.

Authors:  Kyle T Amber; Roberto Maglie; Farzan Solimani; Rüdiger Eming; Michael Hertl
Journal:  Drugs       Date:  2018-10       Impact factor: 9.546

Review 4.  Immune response in pemphigus and beyond: progresses and emerging concepts.

Authors:  Giovanni Di Zenzo; Kyle T Amber; Beyza S Sayar; Eliane J Müller; Luca Borradori
Journal:  Semin Immunopathol       Date:  2015-11-23       Impact factor: 9.623

Review 5.  Pemphigus group: overview, epidemiology, mortality, and comorbidities.

Authors:  Khalaf Kridin
Journal:  Immunol Res       Date:  2018-04       Impact factor: 2.829

6.  Decreased Serum Levels of Interleukin-4 and Interleukin-21 in New Pemphigus Vulgaris Patients, but Not Chronic Patients With Inactive Disease Compared to Healthy Controls.

Authors:  Pegah Shahbazian; Maryam Izad; Maryam Daneshpazhooh; Hossein Mortazavi; Zahra Salehi; Shirin Behruzifar; Soheil Tavakolpour; Arghavan Azizpour
Journal:  Dermatol Pract Concept       Date:  2021-04-12

7.  Serum leptin levels in pemphigus: a case control study.

Authors:  Nikoo Mozafari; Reza M Robati; Shima Younespour
Journal:  Biomed Res Int       Date:  2014-05-12       Impact factor: 3.411

8.  Increased Frequency of T Follicular Helper Cells and Elevated Interleukin-27 Plasma Levels in Patients with Pemphigus.

Authors:  Tina Hennerici; Robert Pollmann; Thomas Schmidt; Maria Seipelt; Björn Tackenberg; Christian Möbs; Kamran Ghoreschi; Michael Hertl; Rüdiger Eming
Journal:  PLoS One       Date:  2016-02-12       Impact factor: 3.240

Review 9.  Non-Desmoglein Antibodies in Patients With Pemphigus Vulgaris.

Authors:  Kyle T Amber; Manuel Valdebran; Sergei A Grando
Journal:  Front Immunol       Date:  2018-06-04       Impact factor: 7.561

10.  Regulatory effects of Nr4a2 on Th2 cells from patients with pemphigus vulgaris.

Authors:  Jianbo Chen; Yao Zhang; Yunsheng Liang; Ming Zhao; Hai Long; Rong Xiao; Haijing Wu; Jieyue Liao; Shuaihantian Luo; Guiying Zhang; Qianjin Lu
Journal:  Oncotarget       Date:  2018-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.